204 related articles for article (PubMed ID: 23340297)
1. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction.
Abiko K; Mandai M; Hamanishi J; Yoshioka Y; Matsumura N; Baba T; Yamaguchi K; Murakami R; Yamamoto A; Kharma B; Kosaka K; Konishi I
Clin Cancer Res; 2013 Mar; 19(6):1363-74. PubMed ID: 23340297
[TBL] [Abstract][Full Text] [Related]
2. PPARγ activation modulates the balance of peritoneal macrophage populations to suppress ovarian tumor growth and tumor-induced immunosuppression.
Prat M; Coulson K; Blot C; Jacquemin G; Romano M; Renoud ML; AlaEddine M; Le Naour A; Authier H; Rahabi MC; Benmoussa K; Salon M; Parny M; Delord JP; Ferron G; Lefèvre L; Couderc B; Coste A
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586764
[TBL] [Abstract][Full Text] [Related]
3. FOXP4-AS1 promotes CD8
Shen GY; Zhang Y; Huang RZ; Huang ZY; Yang LY; Chen DZ; Yang SB
Immunol Res; 2024 Apr; ():. PubMed ID: 38687433
[TBL] [Abstract][Full Text] [Related]
4. Obesity modulates the cellular and molecular microenvironment in the peritoneal cavity: implication for ovarian cancer risk.
Shea AA; Heffron CL; Grieco JP; Roberts PC; Schmelz EM
Front Immunol; 2023; 14():1323399. PubMed ID: 38264656
[TBL] [Abstract][Full Text] [Related]
5. Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer.
Chakrabarti J; Holokai L; Syu L; Steele NG; Chang J; Wang J; Ahmed S; Dlugosz A; Zavros Y
Oncotarget; 2018 Dec; 9(100):37439-37457. PubMed ID: 30647844
[TBL] [Abstract][Full Text] [Related]
6. Electrolyte imbalance causes suppression of NK and T cell effector function in malignant ascites.
Hrvat A; Schmidt M; Wagner B; Zwanziger D; Kimmig R; Volbracht L; Brandau S; Mallmann-Gottschalk N
J Exp Clin Cancer Res; 2023 Sep; 42(1):235. PubMed ID: 37684704
[TBL] [Abstract][Full Text] [Related]
7. Blockade of TGF-β and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses.
Kment J; Newsted D; Young S; Vermeulen MC; Laight BJ; Greer PA; Lan Y; Craig AW
Br J Cancer; 2024 Apr; ():. PubMed ID: 38622286
[TBL] [Abstract][Full Text] [Related]
8. Anti-Tumor Immunogenicity of the Oncolytic Virus CF33-hNIS-antiPDL1 against Ex Vivo Peritoneal Cells from Gastric Cancer Patients.
Zhang Z; Yang A; Chaurasiya S; Park AK; Kim SI; Lu J; Valencia H; Fong Y; Woo Y
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762490
[TBL] [Abstract][Full Text] [Related]
9. Development of a syngeneic mouse model of epithelial ovarian cancer.
Quinn BA; Xiao F; Bickel L; Martin L; Hua X; Klein-Szanto A; Connolly DC
J Ovarian Res; 2010 Oct; 3():24. PubMed ID: 20958993
[TBL] [Abstract][Full Text] [Related]
10. Loss of B1 and marginal zone B cells during ovarian cancer.
Maslanka J; Torres G; Londregan J; Goldman N; Silberman D; Somerville J; Riggs JE
Cell Immunol; 2024; 395-396():104788. PubMed ID: 38000306
[TBL] [Abstract][Full Text] [Related]
11. DC-Derived CXCL10 Promotes CTL Activation to Suppress Ovarian Cancer.
Dong M; Lu L; Xu H; Ruan Z
Transl Res; 2024 May; ():. PubMed ID: 38823437
[TBL] [Abstract][Full Text] [Related]
12. Active Delivery of VLPs Promotes Anti-Tumor Activity in a Mouse Ovarian Tumor Model.
Wang C; Fernández de Ávila BE; Mundaca-Uribe R; Lopez-Ramirez MA; Ramírez-Herrera DE; Shukla S; Steinmetz NF; Wang J
Small; 2020 May; 16(20):e1907150. PubMed ID: 32329580
[TBL] [Abstract][Full Text] [Related]
13. Comparing mouse models of ovarian cancer.
Le Bras A
Lab Anim (NY); 2024 Jan; 53(1):4. PubMed ID: 38172397
[No Abstract] [Full Text] [Related]
14. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
Abiko K; Matsumura N; Hamanishi J; Horikawa N; Murakami R; Yamaguchi K; Yoshioka Y; Baba T; Konishi I; Mandai M
Br J Cancer; 2015 Apr; 112(9):1501-9. PubMed ID: 25867264
[TBL] [Abstract][Full Text] [Related]
15. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer.
Maine CJ; Aziz NH; Chatterjee J; Hayford C; Brewig N; Whilding L; George AJ; Ghaem-Maghami S
Cancer Immunol Immunother; 2014 Mar; 63(3):215-24. PubMed ID: 24297569
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
Duraiswamy J; Freeman GJ; Coukos G
Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
[TBL] [Abstract][Full Text] [Related]
17. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Hamanishi J; Mandai M; Ikeda T; Minami M; Kawaguchi A; Murayama T; Kanai M; Mori Y; Matsumoto S; Chikuma S; Matsumura N; Abiko K; Baba T; Yamaguchi K; Ueda A; Hosoe Y; Morita S; Yokode M; Shimizu A; Honjo T; Konishi I
J Clin Oncol; 2015 Dec; 33(34):4015-22. PubMed ID: 26351349
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
19. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.
Gatalica Z; Snyder C; Maney T; Ghazalpour A; Holterman DA; Xiao N; Overberg P; Rose I; Basu GD; Vranic S; Lynch HT; Von Hoff DD; Hamid O
Cancer Epidemiol Biomarkers Prev; 2014 Dec; 23(12):2965-70. PubMed ID: 25392179
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.
Peng J; Hamanishi J; Matsumura N; Abiko K; Murat K; Baba T; Yamaguchi K; Horikawa N; Hosoe Y; Murphy SK; Konishi I; Mandai M
Cancer Res; 2015 Dec; 75(23):5034-45. PubMed ID: 26573793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
